Abstract:Background: Long-chain PUFA (LC-PUFA) influence varying aspects of inflammation. One mechanism by which they regulate inflammation is by controlling the size and molecular composition of lipid rafts. Lipid rafts are sphingolipid/cholesterol-enriched plasma membrane microdomains that compartmentalize signaling proteins and thereby control downstream inflammatory gene expression and cytokine production. Objectives: This review summarizes developments in our understanding of how LC-PUFA acyl chains of phospholipids, in addition to oxidized derivatives of LC-PUFAs such as oxidized 1-palmitoyl-2-arachidonyl-phosphatidylcholine (oxPAPC), manipulate formation of lipid rafts and thereby inflammation. Methods: We reviewed the literature, largely from the past 2 decades, on the impact of LC-PUFA acyl chains and oxidized products of LC-PUFAs on lipid raft biophysical organization of myeloid and lymphoid cells. The majority of the studies are based on rodent or cellular experiments with supporting mechanistic studies using biomimetic membranes and molecular dynamic simulations. These studies have focused largely on the LC-PUFA docosahexaenoic acid, with some studies addressing eicosapentaenoic acid. A few studies have investigated the role of oxidized phospholipids on rafts. Results: The biophysical literature suggests a model in which n-3 LC-PUFAs, in addition to oxPAPC, localize predominately to nonraft regions and impart a disordering effect in this environment. Rafts become larger because of the ensuing increase in the difference in order between raft and nonrafts. Biochemical studies suggest that some n-3 LC-PUFAs can be found within rafts. This deviation from homeostasis is a potential trigger for controlling aspects of innate and adaptive immunity. Conclusion: Overall, select LC-PUFA acyl chains and oxidized acyl chains of phospholipids control lipid raft dynamics and downstream inflammation. Gaps in knowledge remain, particularly on underlying molecular mechanisms by which plasma membrane receptor organization is controlled in response to oxidized LC-PUFA acyl chains of membrane phospholipids. Validation in humans is also an area for future study.

The role of lipids in the signaling mechanisms of toll-like receptors

The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL

How Membrane Phospholipids Containing Long-Chain Polyunsaturated Fatty Acids and Their Oxidation Products Orchestrate Lipid Raft Dynamics to Control Inflammation

Molecular Mechanism of Oxldl Inducing Lipid Accumulation and Inflammation in Macrophages to Promot Atherosclerosisvia TLR4 Signaling Pathway

Toll-like receptor signaling and atherosclerosis

Postprandial lipoproteins and the molecular regulation of vascular homeostasis

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.

Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease

Toll-like receptors as a part of osteoarthritis pathophysiology: anti-inflammatory, analgesic and neuroprotective effects

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

New Paradigms in Inflammatory Signaling in Vascular Endothelial Cells

Establishing the Structural Rules for Ligand Recognition, Signaling and Assembly in Innate Immune Receptors

Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics

Roles Of Toll-Like Receptors In Nitroxidative Stress In Mammals

Endogenous toll-like receptor ligands and their biological significance.

Posttranslational Modification Control of Inflammatory Signaling

The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling

Lipid Mediators in Health and Disease: Enzymes and Receptors as Therapeutic Targets for the Regulation of Immunity and Inflammation

Lysophospholipids and Their Receptors Serve As Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury.

Modulation of Toll–interleukin 1 receptor mediated signaling